Related Experiment Videos
Antibody-directed therapies for hematological malignancies
Michael L Linenberger1, David G Maloney, Irwin D Bernstein
1Clinical Research Division, Fred Hutchinson Cancer Research Center, and Dept of Medicine, University of Washington, Seattle, WA, USA. linen@u.washington.edu
Trends in Molecular Medicine
|January 30, 2002
Summary
Engineered antibodies targeting specific antigens on cancer cells show promise for treating hematological malignancies. While some therapies are approved, further research is needed to optimize antibody design and treatment strategies.
Area of Science:
- * Hematology and Immunology
- * Oncology
- * Pharmaceutical Sciences
Background:
- * Malignant hematopoietic cells express unique antigens, making them targets for antibody-based therapies.
- * Several engineered antibodies, fragments, and conjugates have been developed for cancer treatment.
- * Only three antibody-based therapies have received clinical approval to date.
Purpose of the Study:
- * To review the development and clinical application of antibody-directed therapies for hematological malignancies.
- * To highlight the success of chimeric mouse-human anti-CD20 antibodies.
- * To discuss the challenges and future directions in rational antibody design for cancer treatment.
Main Methods:
- * Review of existing literature on antibody-directed therapies in hematological malignancies.
- * Analysis of clinical trial data for approved and investigational antibody agents.
- * Evaluation of antibody engineering strategies and target identification.
Main Results:
- * Chimeric mouse-human anti-CD20 antibody has demonstrated significant clinical efficacy.
- * Other approved antibodies and agents in clinical trials show encouraging results.
- * Advances in antibody design suggest potential for future effective treatments.
Conclusions:
- * Antibody-directed therapy is a promising approach for hematological malignancies.
- * Rational antibody design holds potential for developing novel and effective cancer treatments.
- * Ongoing challenges include identifying optimal targets, antibody formats, and treatment schedules.